TYPE,NAME,NODE_ID,source_primary,source_secondary,title,source_link,source_date,pubmed_id,country_of_origin
disease,dementia/parkinsonism with non-Alzheimer amyloid plaques,n_0,,,,,,,
disease,Alzheimer disease,n_4,,,,,,,
disease,"Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology",n_39,,,,,,,
disease,familial Alzheimer disease,n_44,,,,,,,
disease,Alzheimer disease without neurofibrillary tangles,n_133,,,,,,,
disease,"Alzheimer disease, susceptibility to, mitochondrial",n_351,,,,,,,
pathway,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,n_373,,,,,,,
Stage,Mild (MMSE 21-26),n_402,,,,,,,
Stage,Moderate (MMSE 10-20),n_405,,,,,,,
Stage,Severe (MMSE <10),n_408,,,,,,,
Treatment,Donepezil Treatment (NICE),n_420,,,,,,,
Treatment,Rivastigmine Treatment (NICE),n_421,,,,,,,
Treatment,Rivastigmine Patch Treatment (NICE),n_422,,,,,,,
Treatment,Galantamine Treatment (NICE),n_423,,,,,,,
Treatment,Galantamine Treatment moderate hepatic impairment (NICE),n_424,,,,,,,
Treatment,Memantine Treatment (NICE),n_425,,,,,,,
Treatment,Memantine Treatment renal impairment 1 (NICE),n_426,,,,,,,
Treatment,Memantine Treatment renal impairment 2 (NICE),n_427,,,,,,,
Treatment,Memantine Treatment renal impairment 3 (NICE),n_428,,,,,,,
Treatment,Haloperidol Treatment (NICE),n_429,,,,,,,
Treatment,Risperidone Treatment (NICE),n_430,,,,,,,
Step,Donepezil Treatment (NICE) (1),n_434,,,,,,,
Dosage,Donepezil 5mg/day,n_435,,,,,,,
Step,Donepezil Treatment (NICE) (2),n_437,,,,,,,
Step,Galantamine Treatment (NICE) (1),n_444,,,,,,,
Dosage,Galantamine 8mg/day,n_445,,,,,,,
Step,Galantamine Treatment (NICE) (2),n_447,,,,,,,
Dosage,Galantamine 16mg/day,n_448,,,,,,,
Step,Galantamine Treatment (NICE) (3),n_450,,,,,,,
Step,Galantamine Treatment moderate hepatic impairment (NICE) (1),n_454,,,,,,,
Step,Galantamine Treatment moderate hepatic impairment (NICE) (2),n_457,,,,,,,
Dosage,Galantamine 8-16mg/day,n_458,,,,,,,
Step,Rivastigmine Patch Treatment (NICE) (1),n_465,,,,,,,
Dosage,Rivastigmine Patch 4.6mg/day,n_466,,,,,,,
Step,Rivastigmine Patch Treatment (NICE) (2),n_468,,,,,,,
Dosage,Rivastigmine Patch 9.5mg/day,n_469,,,,,,,
Step,Rivastigmine Patch Treatment (NICE) (3),n_471,,,,,,,
drug,Donepezil,n_496,,,,,,,
drug,Galantamine,n_518,,,,,,,
drug,Rivastigmine,n_554,,,,,,,
drug,Memantine,n_595,,,,,,,
drug,Haloperidol,n_614,,,,,,,
drug,Risperidone,n_638,,,,,,,
Therapy,Cognitive Stimulation Therapy,n_666,,,,,,,
Therapy,Reminiscence Therapy,n_667,,,,,,,
Therapy,Behavioral Management,n_668,,,,,,,
Therapy,Music Therapy,n_669,,,,,,,
Treatment,Donepezil Treatment (成大),n_766,,,,,,,
Treatment,Rivastigmine Treatment (成大),n_769,,,,,,,
Treatment,Galantamine Treatment (成大),n_772,,,,,,,
Treatment,Memantine Treatment (成大),n_776,,,,,,,
drug,Rivastigmine Patch,n_785,,,,,,,
Stage,Mild  (ADAS-Cog),n_821,,,,,,,
Stage,Moderate (ADAS-Cog),n_823,,,,,,,
Stage,Severe (ADAS-Cog),n_825,,,,,,,
Treatment,Donepezil Treatment (MaHTAS),n_852,,,,,,,
Treatment,Rivastigmine Patch Treatment (MaHTAS),n_853,,,,,,,
Treatment,Rivastigmine Treatment (MaHTAS),n_854,,,,,,,
Treatment,Galantamine Treatment (MaHTAS),n_855,,,,,,,
Treatment,Memantine Treatment (MaHTAS),n_856,,,,,,,
Therapy,Exercise,n_894,,,,,,,
Therapy,Diet and supplement,n_895,,,,,,,
Therapy,Cognitive enhancing therapy,n_896,,,,,,,
Treatment,Donepezil Treatment (AmericanAcademy of Family Physicians),n_911,,,,,,,
Treatment,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),n_912,,,,,,,
Treatment,Rivastigmine Treatment (AmericanAcademy of Family Physicians),n_913,,,,,,,
Treatment,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),n_914,,,,,,,
Treatment,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),n_915,,,,,,,
Treatment,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),n_916,,,,,,,
Treatment,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),n_917,,,,,,,
Treatment,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),n_918,,,,,,,
Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (1),n_922,,,,,,,
Dosage,5 mg orally at bedtime,n_923,,,,,,,
Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (2),n_925,,,,,,,
Dosage,10 mg orally at bedtime,n_926,,,,,,,
Step,Donepezil Treatment (AmericanAcademy of Family Physicians) (3),n_928,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (1),n_934,,,,,,,
Dosage,1.5 mg orally 2 times per day,n_935,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (2),n_937,,,,,,,
Dosage,3 mg orally 2 times per day,n_938,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),n_940,,,,,,,
Dosage,4.5 mg orally 2 times per day,n_941,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (4),n_943,,,,,,,
Dosage,6 mg orally 2 times per day,n_944,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (5),n_946,,,,,,,
Dosage,7.5 mg orally 2 times per day,n_947,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (6),n_949,,,,,,,
Dosage,9 mg orally 2 times per day,n_950,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (7),n_952,,,,,,,
Dosage,10.5 mg orally 2 times per day,n_953,,,,,,,
Step,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (8),n_955,,,,,,,
Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),n_962,,,,,,,
Dosage,4.6-mg patch every 24 hours,n_963,,,,,,,
Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),n_965,,,,,,,
Dosage,9.5-mg patch every 24 hours,n_966,,,,,,,
Step,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (3),n_968,,,,,,,
Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),n_974,,,,,,,
Dosage,4 mg orally 2 times per day,n_975,,,,,,,
Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),n_977,,,,,,,
Dosage,8 mg 2 times per day,n_978,,,,,,,
Step,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),n_980,,,,,,,
Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),n_986,,,,,,,
Dosage,8 mg orally per day,n_987,,,,,,,
Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),n_989,,,,,,,
Dosage,16 mg per day,n_990,,,,,,,
Step,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),n_992,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),n_998,,,,,,,
Dosage,5 mg orally per day,n_999,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),n_1001,,,,,,,
Dosage,5 mg 2 times per day,n_1002,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),n_1004,,,,,,,
Dosage,10 mg every morning and 5mg every night,n_1005,,,,,,,
Step,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (4),n_1007,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),n_1013,,,,,,,
Dosage,7 mg orally per day,n_1014,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),n_1016,,,,,,,
Dosage,14 mg orally per day,n_1017,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),n_1019,,,,,,,
Dosage,21 mg orally per day,n_1020,,,,,,,
Step,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (4),n_1022,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),n_1030,,,,,,,
Dosage,Memantine:7 mg orally at bedtime,n_1033,,,,,,,
Dosage,Donepezil: 10 mg orally at bedtime,n_1034,,,,,,,
Dosage,"Vitamin E:1,000 IU orally 2 times per day",n_1035,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),n_1037,,,,,,,
Dosage,Memantine:14 mg orally at bedtime,n_1040,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),n_1044,,,,,,,
Dosage,Memantine:21 mg orally at bedtime,n_1047,,,,,,,
Step,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),n_1051,,,,,,,
drug,Vitamin E,n_1090,,,,,,,
Therapy,Enjoyable leisure activities,n_1099,,,,,,,
Therapy,Mental stimulation programs,n_1100,,,,,,,
Therapy,Occupational therapy training in coping strategies and cognitive aides,n_1101,,,,,,,
Therapy,Structured physical exercise programs,n_1102,,,,,,,
Treatment,Donepezil Treatment (Germany),n_1123,,,,,,,
Treatment,Rivastigmine Treatment (Germany),n_1124,,,,,,,
Treatment,Galantamine Treatment (Germany),n_1125,,,,,,,
Treatment,Memantine Treatment (Germany),n_1126,,,,,,,
Treatment,Donepezil Treatment (CDPC),n_1187,,,,,,,
Treatment,Rivastigmine Treatment (CDPC),n_1188,,,,,,,
Treatment,Galantamine Treatment (CDPC),n_1189,,,,,,,
Treatment,Memantine Treatment (CDPC),n_1190,,,,,,,
Therapy,Cognitive stimulation,n_1215,,,,,,,
Therapy,Cognitive training,n_1216,,,,,,,
Therapy,Cognitive rehabilitation,n_1217,,,,,,,
Stage,早期,n_1232,,,,,,,
Stage,中期,n_1237,,,,,,,
Stage,晚期,n_1242,,,,,,,
Treatment,Donepezil Treatment (臺中榮總),n_1248,,,,,,,
Step,Donepezil Treatment (臺中榮總) (1),n_1250,,,,,,,
Dosage,Donepezil 5 mg/day,n_1251,,,,,,,
Step,Donepezil Treatment (臺中榮總) (2),n_1253,,,,,,,
Treatment,Rivastigmine Treatment (臺中榮總),n_1257,,,,,,,
Step,Rivastigmine Treatment (臺中榮總) (1),n_1259,,,,,,,
Dosage,Rivastigmine 1.5 mg/day,n_1260,,,,,,,
Step,Rivastigmine Treatment (臺中榮總) (2),n_1262,,,,,,,
Step,Rivastigmine Treatment (臺中榮總) (3),n_1265,,,,,,,
Treatment,Rivastigmine Patch Treatment (臺中榮總),n_1268,,,,,,,
Step,Rivastigmine Patch Treatment (臺中榮總) (1),n_1270,,,,,,,
Dosage,Rivastigmine Patch 4.6 mg/day,n_1271,,,,,,,
Step,Rivastigmine Patch Treatment (臺中榮總) (2),n_1273,,,,,,,
Treatment,Galantamine Treatment (臺中榮總),n_1276,,,,,,,
Step,Galantamine Treatment (臺中榮總) (1),n_1278,,,,,,,
Step,Galantamine Treatment (臺中榮總) (2),n_1281,,,,,,,
Treatment,Memantine Treatment (臺中榮總),n_1284,,,,,,,
Step,Memantine Treatment (臺中榮總) (1),n_1286,,,,,,,
Step,Memantine Treatment (臺中榮總) (2),n_1289,,,,,,,
Treatment,Memantine Treatment 腎功能不佳者 (臺中榮總),n_1293,,,,,,,
Step,Memantine Treatment 腎功能不佳者 (臺中榮總),n_1294,,,,,,,
Therapy,Cognitive Activities,n_1356,,,,,,,
Therapy,Music Therapy Groups,n_1357,,,,,,,
Therapy,Art Creation,n_1358,,,,,,,
Therapy,Exercise Groups,n_1359,,,,,,,
Therapy,Reality Orientation Therapy,n_1360,,,,,,,
Therapy,Dance Therapy,n_1361,,,,,,,
Therapy,Horticulture Therapy,n_1362,,,,,,,
Therapy,Aromatherapy,n_1363,,,,,,,
Therapy,Pet Therapy,n_1364,,,,,,,
Therapy,Doll Therapy,n_1365,,,,,,,
Therapy,Sensory Stimulation,n_1366,,,,,,,
Stage,Early stage(GDS 2-5),n_1396,,,,,,,
Stage,Middle stage (GDS 4-6),n_1399,,,,,,,
Stage,Late stage (GDS 7),n_1403,,,,,,,
Treatment,Donepezil Treatment (Japanese Society of Neurology),n_1446,,,,,,,
Treatment,Rivastigmine Patch Treatment (Japanese Society of Neurology),n_1447,,,,,,,
Treatment,Rivastigmine Treatment (Japanese Society of Neurology),n_1448,,,,,,,
Treatment,Galantamine Treatment (Japanese Society of Neurology),n_1449,,,,,,,
Treatment,Combined Donepezil and Memantine Treatment (Japanese Society of Neurology),n_1450,,,,,,,
Treatment,Memantine Treatment (Japanese Society of Neurology),n_1451,,,,,,,
Treatment,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),n_1473,,,,,,,
Therapy,Exercise therapy,n_1479,,,,,,,
Therapy,Music therapy,n_1480,,,,,,,
Stage,(MCI) due to Alzheimer's disease,n_1483,,,,,,,
Stage,Early stage(mild),n_1485,,,,,,,
Stage,Middle stage (moderate),n_1491,,,,,,,
Stage,Late stage (severe),n_1497,,,,,,,
Stage,MCI due to Alzheimer's disease,n_1500,,,,,,,
Treatment,Donanemab Treatment (Alzheimer's Association),n_1523,,,,,,,
Treatment,Lecanemab (Alzheimer's Association),n_1526,,,,,,,
Treatment,Donepezil Treatment (Alzheimer's Association),n_1529,,,,,,,
Treatment,Rivastigmine Treatment (Alzheimer's Association),n_1532,,,,,,,
Treatment,Galantamine Treatment (Alzheimer's Association),n_1535,,,,,,,
Treatment,Memantine Treatment (Alzheimer's Association),n_1538,,,,,,,
Treatment,Memantine + Donepezil (Alzheimer's Association),n_1541,,,,,,,
Treatment,Brexpiprazole Treatment (Alzheimer's Association),n_1545,,,,,,,
Treatment,Suvorexant Treatment (Alzheimer's Association),n_1548,,,,,,,
drug,Donanemab,n_1551,,,,,,,
drug,Lecanemab,n_1553,,,,,,,
drug,Brexpiprazole,n_1573,,,,,,,
drug,Suvorexant,n_1578,,,,,,,
Treatment,Donepezil Treatment (NHG),n_1614,,,,,,,
Treatment,Galantamine Treatment (NHG),n_1618,,,,,,,
Treatment,Memantine Treatment (NHG),n_1622,,,,,,,
Treatment,Rivastigmine Treatment (NHG),n_1626,,,,,,,
Treatment,Donepezil Treatment (Kaypahoito),n_1651,,,,,,,
Treatment,Galantamine Treatment (Kaypahoito),n_1655,,,,,,,
Treatment,Memantine Treatment (Kaypahoito),n_1659,,,,,,,
Treatment,Rivastigmine Treatment (Kaypahoito),n_1663,,,,,,,
Treatment,Donepezil Treatment (Indian Psychiatric Society),n_1703,,,,,,,
Dosage,5mg daily,n_1705,,,,,,,
Treatment,Galantamine Treatment (Indian Psychiatric Society),n_1709,,,,,,,
Dosage,8mg daily,n_1711,,,,,,,
Treatment,Memantine Treatment (Indian Psychiatric Society),n_1715,,,,,,,
Treatment,Rivastigmine Treatment (Indian Psychiatric Society),n_1721,,,,,,,
Dosage,3mg daily,n_1723,,,,,,,
drug,cholinesterase inhibitors,n_1744,,,,,,,
drug,memantine,n_1745,,,,,,,
Withdrawal,cholinesterase inhibitors_CaroleParsons,n_1746,,,,,,,
Withdrawal,memantine_CaroleParsons,n_1747,,,,,,,
drug,Statins,n_1749,,,,,,,
drug,melatonin,n_1754,,,,,,,
drug,melatonin receptor agonist,n_1755,,,,,,,
drug,trazodone,n_1756,,,,,,,
drug,orexin antagonists,n_1757,,,,,,,
Treatment,Memantine_RupertMcShane,n_1763,,,,,,,
drug,Aspirin,n_1768,,,,,,,
drug,cyclo‐oxygenase‐2,n_1769,,,,,,,
drug, non‐selective NSAID naproxen,n_1770,,,,,,,
drug,celecoxib,n_1771,,,,,,,
drug,COX‐2 inhibitor rofecoxib,n_1772,,,,,,,
Prevent,Aspirin_FionnualaJordan,n_1773,,,,,,,
Dosage,100mg/day,n_1774,,,,,,,
Prevent,cyclo‐oxygenase‐2 and non‐selective NSAID naproxen_FionnualaJordan,n_1775,,,,,,,
Dosage,cyclo‐oxygenase‐2 200 mg twice daily,n_1776,,,,,,,
Dosage, non‐selective NSAID naproxen 220 mg twice daily,n_1778,,,,,,,
Prevent,celecoxib_FionnualaJordan,n_1779,,,,,,,
Dosage,200 mg or 400 mg daily,n_1780,,,,,,,
Prevent,COX‐2 inhibitor rofecoxib_FionnualaJordan,n_1781,,,,,,,
Dosage,25 mg once daily,n_1782,,,,,,,
drug,Cerebrolysin,n_1784,,,,,,,
Treatment,Donepezil_CeriEBattle,n_1793,,,,,,,
Treatment,Galantamine_CeriEBattle,n_1794,,,,,,,
Treatment,Rivastigmine_CeriEBattle,n_1795,,,,,,,
drug,vitamin B6,n_1799,,,,,,,
drug,vitamin B12,n_1800,,,,,,,
drug,vitamin E ,n_1801,,,,,,,
drug,Souvenaid,n_1803,,,,,,,
Treatment,Souvenaid_MarionBurckhardt,n_1806,,,,,,,
drug,Latrepirdine,n_1808,,,,,,,
Treatment,Latrepirdine_SarahChau,n_1812,,,,,,,
Treatment,Rivastigmine_Jacqueline S Birks,n_1817,,,,,,,
Dosage,6 to 12 mg/day orally or 9.5 mg/day transdermally ,n_1818,,,,,,,
Treatment,Donepezil_Jacqueline S Birks,n_1824,,,,,,,
Dosage,10mg/day,n_1825,,,,,,,
drug,Cannabinoid,n_1827,,,,,,,
Treatment,Cannabinoid_Dina Bosnjak Kuharic,n_1831,,,,,,,
Intervention,Dance movement,n_1833,,,,,,,
Treatment,Galantamine_Amanda Wei Yin Lim,n_1838,,,,,,,
Dosage,16~24mg/day,n_1839,,,,,,,
drug,Omega‐3 fatty acid,n_1841,,,,,,,
Treatment,Omega‐3 fatty acid_Marion Burckhardt,n_1844,,,,,,,
Treatment,Vitamin E_Nicolas Farina,n_1847,,,,,,,
drug,Antipsychotic,n_1849,,,,,,,
drug,Antihypertensive,n_1851,,,,,,,
Prevent,Antihypertensive_Emma L Cunningham,n_1852,,,,,,,
effect/phenotype,Parkinsonism,n_1890,,,,,,,
effect/phenotype,Dementia,n_1891,,,,,,,
effect/phenotype,Substantia nigra gliosis,n_1892,,,,,,,
effect/phenotype,Autosomal dominant inheritance,n_1893,,,,,,,
effect/phenotype,Dysphagia,n_1894,,,,,,,
effect/phenotype,Optic ataxia,n_1895,,,,,,,
effect/phenotype,Gait disturbance,n_1896,,,,,,,
effect/phenotype,Memory impairment,n_1897,,,,,,,
effect/phenotype,Babinski sign,n_1898,,,,,,,
effect/phenotype,Seizure,n_1899,,,,,,,
effect/phenotype,Cerebral cortical atrophy,n_1900,,,,,,,
effect/phenotype,Apraxia,n_1901,,,,,,,
effect/phenotype,Lower limb hyperreflexia,n_1902,,,,,,,
effect/phenotype,Dysarthria,n_1903,,,,,,,
effect/phenotype,Spastic tetraparesis,n_1904,,,,,,,
effect/phenotype,Adult onset,n_1905,,,,,,,
effect/phenotype,Neurofibrillary tangles,n_1906,,,,,,,
effect/phenotype,Abnormality of extrapyramidal motor function,n_1907,,,,,,,
effect/phenotype,Agnosia,n_1908,,,,,,,
effect/phenotype,Personality changes,n_1910,,,,,,,
effect/phenotype,Myoclonus,n_1912,,,,,,,
effect/phenotype,Rapidly progressive,n_1913,,,,,,,
effect/phenotype,Decreased level of GABA in serum,n_1915,,,,,,,
effect/phenotype,Long-tract signs,n_1916,,,,,,,
effect/phenotype,Heterogeneous,n_1917,,,,,,,
effect/phenotype,Sleep-wake cycle disturbance,n_1918,,,,,,,
effect/phenotype,Middle age onset,n_1919,,,,,,,
effect/phenotype,Cognitive impairment,n_1920,,,,,,,
effect/phenotype,Parietal hypometabolism in FDG PET,n_1921,,,,,,,
effect/phenotype,Cerebral amyloid angiopathy,n_1922,,,,,,,
effect/phenotype,Senile plaques,n_1923,,,,,,,
effect/phenotype,Depressivity,n_1924,,,,,,,
effect/phenotype,Disinhibition,n_1925,,,,,,,
effect/phenotype,Hippocampal atrophy,n_1926,,,,,,,
effect/phenotype,Late onset,n_1927,,,,,,,
effect/phenotype,Neurological speech impairment,n_1928,,,,,,,
effect/phenotype,Cerebral cortex with spongiform changes,n_1930,,,,,,,
effect/phenotype,Behavioral abnormality,n_1934,,,,,,,
effect/phenotype,Emotional lability,n_1935,,,,,,,
effect/phenotype,Anxiety,n_1937,,,,,,,
effect/phenotype,Specific learning disability,n_1938,,,,,,,
effect/phenotype,Sleep disturbance,n_1939,,,,,,,
effect/phenotype,Deficit in phonologic short-term memory,n_1940,,,,,,,
effect/phenotype,Attention deficit hyperactivity disorder,n_1941,,,,,,,
effect/phenotype,Abdominal symptom,n_1942,,,,,,,
effect/phenotype,Perseveration,n_1943,,,,,,,
effect/phenotype,Jaw pain,n_1944,,,,,,,
effect/phenotype,Agitation,n_1946,,,,,,,
effect/phenotype,Hallucinations,n_1947,,,,,,,
effect/phenotype,Hypertonia,n_1948,,,,,,,
effect/phenotype,Confusion,n_1949,,,,,,,
effect/phenotype,Deposits immunoreactive to beta-amyloid protein,n_1950,,,,,,,
effect/phenotype,Abnormal social behavior,n_1951,,,,,,,
effect/phenotype,Neurodevelopmental abnormality,n_1952,,,,,,,
effect/phenotype,Abnormality of vision,n_1953,,,,,,,
effect/phenotype,Oculomotor apraxia,n_1954,,,,,,,
effect/phenotype,Intellectual disability,n_1955,,,,,,,
effect/phenotype,Ataxia,n_1956,,,,,,,
effect/phenotype,Aphasia,n_1957,,,,,,,
effect/phenotype,Abnormality of higher mental function,n_1958,,,,,,,
effect/phenotype,Semantic dementia,n_1959,,,,,,,
drug,Phenyltoloxamine,n_1965,,,,,,,
drug,Pheniramine,n_1966,,,,,,,
drug,Orphenadrine,n_1967,,,,,,,
drug,Pravastatin,n_1968,,,,,,,
drug,Carisoprodol,n_1969,,,,,,,
drug,Citric acid,n_1970,,,,,,,
drug,Butalbital,n_1971,,,,,,,
drug,Codeine,n_1972,,,,,,,
drug,Oxycodone,n_1973,,,,,,,
drug,Trolnitrate,n_1974,,,,,,,
drug,Salicylamide,n_1975,,,,,,,
drug,Phenacetin,n_1976,,,,,,,
drug,Phenylephrine,n_1977,,,,,,,
drug,Dipyridamole,n_1978,,,,,,,
drug,Caffeine,n_1979,,,,,,,
drug,Meprobamate,n_1980,,,,,,,
drug,Methocarbamol,n_1981,,,,,,,
drug,Phenobarbital,n_1982,,,,,,,
drug,Dextropropoxyphene,n_1983,,,,,,,
drug,Pentazocine,n_1984,,,,,,,
drug,Calcium gluconate,n_1985,,,,,,,
drug,Phenylpropanolamine,n_1986,,,,,,,
drug,Chlorpheniramine,n_1987,,,,,,,
drug,Hydrocodone,n_1988,,,,,,,
drug,Dihydrocodeine,n_1989,,,,,,,
drug,Epicriptine,n_1990,,,,,,,
drug,Perazine,n_1991,,,,,,,
drug,Alimemazine,n_1992,,,,,,,
drug,Isopropamide,n_1993,,,,,,,
drug,Molindone,n_1994,,,,,,,
drug,Fluphenazine,n_1995,,,,,,,
drug,Pramiracetam,n_1996,,,,,,,
drug,Methotrimeprazine,n_1997,,,,,,,
drug,Promazine,n_1998,,,,,,,
drug,Perphenazine,n_1999,,,,,,,
drug,Prochlorperazine,n_2000,,,,,,,
drug,Clozapine,n_2001,,,,,,,
drug,Fluoxetine,n_2002,,,,,,,
drug,Chlorpromazine,n_2004,,,,,,,
drug,Thioridazine,n_2005,,,,,,,
drug,Amitriptyline,n_2006,,,,,,,
drug,Propiomazine,n_2007,,,,,,,
drug,Thiothixene,n_2008,,,,,,,
drug,Acetylcarnitine,n_2009,,,,,,,
drug,Acetophenazine,n_2010,,,,,,,
drug,Pimozide,n_2011,,,,,,,
drug,Loxapine,n_2012,,,,,,,
drug,Ziprasidone,n_2013,,,,,,,
drug,Triflupromazine,n_2014,,,,,,,
drug,Paliperidone,n_2015,,,,,,,
drug,Iloperidone,n_2016,,,,,,,
drug,Olanzapine,n_2017,,,,,,,
drug,Aripiprazole,n_2018,,,,,,,
drug,Trifluoperazine,n_2019,,,,,,,
drug,Chlorprothixene,n_2020,,,,,,,
drug,Quetiapine,n_2021,,,,,,,
drug,Asenapine,n_2024,,,,,,,
drug,Ipidacrine,n_2026,,,,,,,
drug,Tacrine,n_2030,,,,,,,
effect/phenotype,Morphological central nervous system abnormality,n_2038,,,,,,,
gene/protein,A2M,n_2039,,,,,,,
gene/protein,ACHE,n_2041,,,,,,,
gene/protein,ADAM10,n_2043,,,,,,,
gene/protein,AMFR,n_2045,,,,,,,
gene/protein,BIN1,n_2047,,,,,,,
gene/protein,APOC1,n_2049,,,,,,,
gene/protein,APOE,n_2051,,,,,,,
gene/protein,APP,n_2053,,,,,,,
gene/protein,ATP5F1A,n_2055,,,,,,,
gene/protein,BAX,n_2057,,,,,,,
gene/protein,BCHE,n_2059,,,,,,,
gene/protein,BCL2,n_2061,,,,,,,
gene/protein,BDNF,n_2063,,,,,,,
gene/protein,CALM1,n_2065,,,,,,,
gene/protein,CASP3,n_2067,,,,,,,
gene/protein,CD33,n_2069,,,,,,,
gene/protein,CHRNA7,n_2071,,,,,,,
gene/protein,CHRNB2,n_2073,,,,,,,
gene/protein,CLU,n_2075,,,,,,,
gene/protein,TPP1,n_2077,,,,,,,
gene/protein,CR1,n_2079,,,,,,,
gene/protein,CRH,n_2081,,,,,,,
gene/protein,CST3,n_2083,,,,,,,
gene/protein,CYP2D6,n_2085,,,,,,,
gene/protein,ACE,n_2087,,,,,,,
gene/protein,DHCR24,n_2089,,,,,,,
gene/protein,DPYSL2,n_2091,,,,,,,
gene/protein,EIF2S1,n_2093,,,,,,,
gene/protein,ENO1,n_2095,,,,,,,
gene/protein,EPHA1,n_2097,,,,,,,
gene/protein,ESR1,n_2099,,,,,,,
gene/protein,F2,n_2101,,,,,,,
gene/protein,GSK3B,n_2103,,,,,,,
gene/protein,HFE,n_2105,,,,,,,
gene/protein,HLA-DRB5,n_2107,,,,,,,
gene/protein,HMOX1,n_2109,,,,,,,
gene/protein,IDE,n_2111,,,,,,,
gene/protein,IGF1,n_2113,,,,,,,
gene/protein,IGF1R,n_2115,,,,,,,
gene/protein,IGF2,n_2117,,,,,,,
gene/protein,IGF2R,n_2119,,,,,,,
gene/protein,IL1B,n_2121,,,,,,,
gene/protein,INS,n_2123,,,,,,,
gene/protein,INPP5D,n_2125,,,,,,,
gene/protein,INSR,n_2127,,,,,,,
gene/protein,LEP,n_2129,,,,,,,
gene/protein,MAOB,n_2131,,,,,,,
gene/protein,MAPT,n_2133,,,,,,,
gene/protein,MPO,n_2135,,,,,,,
gene/protein,MTHFR,n_2137,,,,,,,
gene/protein,NOS3,n_2139,,,,,,,
gene/protein,NPY,n_2141,,,,,,,
gene/protein,PLAU,n_2143,,,,,,,
gene/protein,PLCG2,n_2145,,,,,,,
gene/protein,PPARG,n_2147,,,,,,,
gene/protein,PRNP,n_2149,,,,,,,
gene/protein,RELN,n_2151,,,,,,,
gene/protein,PSEN1,n_2153,,,,,,,
gene/protein,PSEN2,n_2155,,,,,,,
gene/protein,PYY,n_2157,,,,,,,
gene/protein,NECTIN2,n_2159,,,,,,,
gene/protein,SLC2A4,n_2161,,,,,,,
gene/protein,SOD2,n_2163,,,,,,,
gene/protein,SORL1,n_2165,,,,,,,
gene/protein,TF,n_2167,,,,,,,
gene/protein,TFAM,n_2169,,,,,,,
gene/protein,TNF,n_2171,,,,,,,
gene/protein,TPI1,n_2173,,,,,,,
gene/protein,VEGFA,n_2175,,,,,,,
gene/protein,VSNL1,n_2177,,,,,,,
gene/protein,SLC30A4,n_2179,,,,,,,
gene/protein,PICALM,n_2181,,,,,,,
gene/protein,UNC5C,n_2183,,,,,,,
gene/protein,ADAMTS1,n_2185,,,,,,,
gene/protein,ABCA7,n_2187,,,,,,,
gene/protein,TOMM40,n_2189,,,,,,,
gene/protein,PGRMC1,n_2191,,,,,,,
gene/protein,CYP46A1,n_2193,,,,,,,
gene/protein,ARC,n_2195,,,,,,,
gene/protein,NCSTN,n_2197,,,,,,,
gene/protein,CD2AP,n_2199,,,,,,,
gene/protein,BACE1,n_2201,,,,,,,
gene/protein,GAPDHS,n_2203,,,,,,,
gene/protein,PCDH11X,n_2205,,,,,,,
gene/protein,ABI3,n_2207,,,,,,,
gene/protein,MS4A4A,n_2209,,,,,,,
gene/protein,WWOX,n_2211,,,,,,,
gene/protein,TREM2,n_2213,,,,,,,
gene/protein,SLC30A6,n_2215,,,,,,,
gene/protein,CASS4,n_2217,,,,,,,
gene/protein,IQCK,n_2219,,,,,,,
gene/protein,MIR100,n_2221,,,,,,,
gene/protein,MIR146A,n_2223,,,,,,,
gene/protein,MIR296,n_2225,,,,,,,
gene/protein,MIR375,n_2227,,,,,,,
gene/protein,MIR505,n_2229,,,,,,,
gene/protein,MIR766,n_2231,,,,,,,
gene/protein,MIR708,n_2233,,,,,,,
gene/protein,SNAR-I,n_2235,,,,,,,
gene/protein,MIR3622B,n_2237,,,,,,,
gene/protein,MIR4467,n_2239,,,,,,,
gene/protein,ND1,n_2241,,,,,,,
gene/protein,ND2,n_2242,,,,,,,
disease,tauopathy,n_2244,,,,,,,
disease,dementia (disease),n_2245,,,,,,,
disease,Mendelian disease,n_2246,,,,,,,
disease,inherited disease susceptibility,n_2250,,,,,,,
disease,autosomal dominant disease,n_2251,,,,,,,
disease,inherited neurodegenerative disorder,n_2252,,,,,,,
disease,genetic dementia,n_2253,,,,,,,
disease,inherited prion disease,n_2254,,,,,,,
exposure,Aluminum,n_2255,,,,,,,
exposure,Cadmium,n_2256,,,,,,,
exposure,Metals,n_2257,,,,,,,
exposure,Nitrogen Oxides,n_2258,,,,,,,
exposure,Ozone,n_2259,,,,,,,
exposure,Particulate Matter,n_2260,,,,,,,
exposure,Pesticides,n_2261,,,,,,,
exposure,Silicon Dioxide,n_2262,,,,,,,
pathway,Neurodegenerative Diseases,n_2263,,,,,,,
gene/protein,BCL2L11,n_2264,,,,,,,
gene/protein,CDK5,n_2265,,,,,,,
gene/protein,FOXO3,n_2266,,,,,,,
gene/protein,GOLGA2,n_2267,,,,,,,
gene/protein,FASLG,n_2269,,,,,,,
gene/protein,JUN,n_2270,,,,,,,
gene/protein,LMNA,n_2271,,,,,,,
gene/protein,LMNB1,n_2272,,,,,,,
gene/protein,PRDX1,n_2273,,,,,,,
gene/protein,PRDX2,n_2275,,,,,,,
gene/protein,YWHAE,n_2276,,,,,,,
gene/protein,CAPN1,n_2277,,,,,,,
gene/protein,CAPN2,n_2278,,,,,,,
gene/protein,CAPNS1,n_2279,,,,,,,
gene/protein,CAST,n_2280,,,,,,,
gene/protein,CAPNS2,n_2281,,,,,,,
gene/protein,CDK5R1,n_2282,,,,,,,
gene/protein,CDC25A,n_2283,,,,,,,
gene/protein,CDC25B,n_2284,,,,,,,
gene/protein,CDC25C,n_2285,,,,,,,
Phenotypes,Difficulty learning new information,n_2293,,,,,,,
Phenotypes,Subtle language problems,n_2294,,,,,,,
Phenotypes,Significant memory loss,n_2295,,,,,,,
Phenotypes,Confusion in daily activities,n_2296,,,,,,,
Phenotypes,Behavioral changes,n_2297,,,,,,,
Phenotypes,Severe memory loss,n_2298,,,,,,,
Phenotypes,Complete dependence on others,n_2299,,,,,,,
Phenotypes,Physical symptoms,n_2300,,,,,,,
Evidence,High quality (Level A),n_2310,,,,,,,
Duration,1 month,n_2325,,,,,,,
Dosage,Donepezil 10mg/day,n_2327,,,,,,,
Population,increased if tolerated and necessary,n_2328,,,,,,,
Effectiveness,Significant improvement in cognitive scores and daily activities,n_2329,,,,,,,
Population,Mild to Severe Alzheimer's Disease (MMSE 0-26),n_2330,,,,,,,
Duration,4 week,n_2335,,,,,,,
Duration,least 4 week,n_2338,,,,,,,
Dosage,Galantamine 16-24mg/day,n_2340,,,,,,,
Duration,1 week,n_2345,,,,,,,
Population,moderate hepatic impairment,n_2349,,,,,,,
Dosage,Rivastigmine 1.5-6.0 twice daily,n_2351,,,,,,,
Duration,6 week,n_2359,,,,,,,
Dosage,Rivastigmine Patch 13.3mg/day,n_2361,,,,,,,
Dosage,Memantine 5-20 mg/day,n_2365,,,,,,,
Effectiveness,Significant improvement in cognitive decline and behavioral symptoms,n_2366,,,,,,,
Population,Moderate to severe Alzheimer's Disease (MMSE < 20),n_2367,,,,,,,
Dosage,Memantine 10-20 mg/day,n_2370,,,,,,,
Population,eGFR is 30–49 mL/minute/1.73 m²,n_2372,,,,,,,
Dosage,Memantine 10 mg/day,n_2375,,,,,,,
Population,eGFR is 5 - 29 mL/minute/1.73 m²,n_2377,,,,,,,
Dosage,Haloperidol 0.5-5 mg/day,n_2380,,,,,,,
Duration,no more than 6 weeks,n_2381,,,,,,,
Dosage,Risperidone 0.5-5 mg/day,n_2384,,,,,,,
SideEffect,Nausea,n_2386,,,,,,,
SideEffect,Vomiting,n_2387,,,,,,,
SideEffect,Anorexia,n_2388,,,,,,,
SideEffect,Diarrhea,n_2389,,,,,,,
SideEffect,Muscle cramps,n_2390,,,,,,,
SideEffect,Syncope,n_2391,,,,,,,
SideEffect,Headache,n_2392,,,,,,,
SideEffect,Dizziness,n_2393,,,,,,,
SideEffect,Abnormal dreams,n_2394,,,,,,,
SideEffect,Hallucinations,n_2395,,,,,,,
SideEffect,Agitation,n_2396,,,,,,,
SideEffect,Aggression,n_2397,,,,,,,
SideEffect,Urinary incontinence,n_2398,,,,,,,
SideEffect,Rash,n_2399,,,,,,,
SideEffect,Pruritus,n_2400,,,,,,,
SideEffect,Extrapyramidal symptoms,n_2401,,,,,,,
SideEffect,Sinoatrial block,n_2402,,,,,,,
SideEffect,Atrioventricular (AV) block,n_2403,,,,,,,
SideEffect,Liver dysfunction (including hepatitis),n_2404,,,,,,,
SideEffect,Neuroleptic malignant syndrome (NMS),n_2405,,,,,,,
SideEffect,Fatigue,n_2406,,,,,,,
SideEffect,Insomnia,n_2407,,,,,,,
SideEffect,Abdominal pain,n_2410,,,,,,,
SideEffect,Diarrhoea,n_2411,,,,,,,
SideEffect,Dyspepsia,n_2412,,,,,,,
SideEffect,Decreased appetite,n_2413,,,,,,,
SideEffect,Weight loss ,n_2414,,,,,,,
SideEffect,Bradycardia,n_2415,,,,,,,
SideEffect,Hypertension,n_2416,,,,,,,
SideEffect,Depression,n_2419,,,,,,,
SideEffect,Tremor,n_2421,,,,,,,
SideEffect,Malaise,n_2424,,,,,,,
SideEffect,Muscle spasm,n_2425,,,,,,,
SideEffect,Retching,n_2426,,,,,,,
SideEffect,Dehydration,n_2427,,,,,,,
SideEffect,Hypotension,n_2428,,,,,,,
SideEffect,Flushing,n_2429,,,,,,,
SideEffect,Palpitation,n_2430,,,,,,,
SideEffect,Arrhythmias,n_2431,,,,,,,
SideEffect,First-degree AV block,n_2432,,,,,,,
SideEffect,Taste disturbance,n_2433,,,,,,,
SideEffect,Paraesthesia,n_2434,,,,,,,
SideEffect,Seizures,n_2435,,,,,,,
SideEffect,Hypersomnia,n_2436,,,,,,,
SideEffect,Muscular weakness,n_2437,,,,,,,
SideEffect,Blurred vision,n_2438,,,,,,,
SideEffect,Tinnitus,n_2439,,,,,,,
SideEffect,Sweating,n_2440,,,,,,,
SideEffect,Exacerbation of Parkinson's disease,n_2441,,,,,,,
SideEffect,Hepatitis,n_2442,,,,,,,
SideEffect,Serious skin reactions,n_2443,,,,,,,
SideEffect,Weight loss,n_2449,,,,,,,
SideEffect,Drowsiness,n_2454,,,,,,,
SideEffect,Gait abnormalities,n_2455,,,,,,,
SideEffect,Fall,n_2456,,,,,,,
SideEffect,Anxiety,n_2459,,,,,,,
SideEffect,Confusion,n_2461,,,,,,,
SideEffect,Parkinsonism,n_2463,,,,,,,
SideEffect,Skin reactions,n_2465,,,,,,,
SideEffect,Urinary tract infection,n_2466,,,,,,,
SideEffect,Atrial fibrillation,n_2469,,,,,,,
SideEffect,AV block,n_2470,,,,,,,
SideEffect,Gastric and duodenal ulceration,n_2474,,,,,,,
SideEffect,Pancreatitis,n_2475,,,,,,,
SideEffect,Angina,n_2476,,,,,,,
SideEffect,Restlessness,n_2481,,,,,,,
SideEffect,Sick sinus syndrome,n_2482,,,,,,,
SideEffect,Tachycardia,n_2483,,,,,,,
SideEffect,Constipation,n_2485,,,,,,,
SideEffect,Dyspnoea,n_2487,,,,,,,
SideEffect,Impaired balance,n_2490,,,,,,,
SideEffect,Thrombosis,n_2493,,,,,,,
SideEffect,Heart failure,n_2494,,,,,,,
SideEffect,Abnormal gait,n_2498,,,,,,,
SideEffect,Psychosis,n_2501,,,,,,,
SideEffect,Suicidal ideation,n_2503,,,,,,,
SideEffect,Weight gain,n_2505,,,,,,,
SideEffect,Dyslipidaemia,n_2506,,,,,,,
SideEffect,Hyperprolactinaemia,n_2507,,,,,,,
SideEffect,Sedation,n_2508,,,,,,,
SideEffect,Sleep apnoea syndrome,n_2509,,,,,,,
SideEffect,Anticholinergic effects,n_2510,,,,,,,
SideEffect,Postural hypotension,n_2511,,,,,,,
SideEffect,Reduced seizure threshold,n_2513,,,,,,,
SideEffect,Impaired glucose tolerance,n_2514,,,,,,,
SideEffect,"Cardiomyopathy, myocarditis, and cutaneous vasculitis",n_2515,,,,,,,
SideEffect,QT interval prolongation,n_2516,,,,,,,
SideEffect,Stroke risk,n_2517,,,,,,,
SideEffect,Venous thromboembolism (VTE),n_2518,,,,,,,
SideEffect,Pneumonia,n_2520,,,,,,,
SideEffect,Neutropenia,n_2521,,,,,,,
SideEffect,Abnormal liver function tests (LFTs),n_2522,,,,,,,
SideEffect,Photosensitivity,n_2523,,,,,,,
SideEffect,Skin and subcutaneous tissue disorders,n_2524,,,,,,,
SideEffect,Diplopia,n_2525,,,,,,,
SideEffect,Misuse and abuse,n_2526,,,,,,,
SideEffect,Restless legs syndrome,n_2527,,,,,,,
Effectiveness,Improves memory attention and social interaction,n_2556,,,,,,,
Effectiveness,Helps maintain long-term memory improves mood,n_2557,,,,,,,
Effectiveness,Reduces anxiety and agitation improves daily functioning,n_2558,,,,,,,
Effectiveness,Improves mood reduces agitation provides positive emotions,n_2559,,,,,,,
Phenotypes,Severe cardiac arrhythmia,n_2560,,,,,,,
Phenotypes,Pregnancy and breastfeeding.,n_2561,,,,,,,
Phenotypes,"Known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipients used in the formulation",n_2562,,,,,,,
Phenotypes,"History of bradycardia, heart block, recurrent unexplained syncope.",n_2563,,,,,,,
Phenotypes,Concurrent treatment with drugs that reduce heart rate.,n_2564,,,,,,,
Phenotypes,Sick sinus syndrome or other supraventricular conduction abnormalities.,n_2565,,,,,,,
Phenotypes,Susceptibility to peptic ulcers including concurrent nonsteroidal anti inflammatory (NSAID) use.,n_2566,,,,,,,
Phenotypes,Asthma and chronic obstructive pulmonary disease (COPD).,n_2567,,,,,,,
Phenotypes,Hepatic impairment. ,n_2568,,,,,,,
Phenotypes,Concomitant antipsychotic treatment — increased risk of neuroleptic malignant syndrome (NMS).,n_2569,,,,,,,
Phenotypes,Hypersensitivity to galantamine or to any of the excipients.,n_2571,,,,,,,
Phenotypes,Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 9 mL/minute/1.73 m²).,n_2572,,,,,,,
Phenotypes,Severe hepatic impairment (Child-Pugh score greater than 9).,n_2573,,,,,,,
Phenotypes,People who have both significant renal and hepatic dysfunction.,n_2574,,,,,,,
Phenotypes,Urinary outflow obstruction.,n_2575,,,,,,,
Phenotypes,Gastrointestinal obstruction.,n_2576,,,,,,,
Phenotypes,During recovery from bladder or gastrointestinal surgery.,n_2577,,,,,,,
Phenotypes,Renal and hepatic impairment.,n_2579,,,,,,,
Phenotypes,"Cardiac disease or in those who use medicinal products that significantly reduce heart rate concomitantly, such as digoxin and beta blockers.",n_2580,,,,,,,
Phenotypes,QTc interval prolongation or taking drugs that prolong the QTc interval.,n_2581,,,,,,,
Phenotypes,Electrolyte disturbances (such as hyperkalaemia or hypokalaemia).,n_2582,,,,,,,
Phenotypes,"Susceptibility to peptic ulcers, including concomitant use of NSAIDs.",n_2583,,,,,,,
Phenotypes,"History of severe asthma, COPD, or pulmonary infection.",n_2584,,,,,,,
Phenotypes,History of seizures.,n_2585,,,,,,,
Phenotypes,"Known hypersensitivity to rivastigmine, other carbamate derivatives, or to any of the excipients used in the formulation.",n_2586,,,,,,,
Phenotypes,Previous history of application site reactions suggestive of allergic contact dermatitis with the rivastigmine patch.,n_2587,,,,,,,
Phenotypes,Hepatic impairment.,n_2589,,,,,,,
Phenotypes,Renal impairment.,n_2590,,,,,,,
Phenotypes,Gastric or duodenal ulcers (or susceptibility to ulcers).,n_2591,,,,,,,
Phenotypes,Sick sinus syndrome or conduction abnormalities.,n_2592,,,,,,,
Phenotypes,History of asthma or COPD.,n_2593,,,,,,,
Phenotypes,Bladder outflow obstruction.,n_2595,,,,,,,
Phenotypes,"Pre-existing, or a family history of, QT interval prolongation.",n_2596,,,,,,,
Phenotypes,Higher risk of developing torsade de pointes,n_2597,,,,,,,
Phenotypes,"Hypersensitivity to the active substance or to any of the excipients, including people with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.",n_2598,,,,,,,
Phenotypes,Severe hepatic impairment.,n_2599,,,,,,,
Phenotypes,Severe renal impairment — memantine hydrochloride should be avoided if the estimated glomerular filtration rate (eGFR) is less than 5 mL/minute/1.73 m².,n_2600,,,,,,,
Phenotypes,History of convulsions or predisposing factors for epilepsy. ,n_2601,,,,,,,
Phenotypes,Severe renal impairment,n_2602,,,,,,,
Phenotypes,"Central nervous system depression, comatose states.",n_2603,,,,,,,
Phenotypes,"Congenital long QT syndrome, history of Torsade de Pointes, QTc interval",n_2604,,,,,,,
Phenotypes,"prolongation, concurrent use with drugs that prolong the QT interval, history of",n_2605,,,,,,,
Phenotypes,"ventricular arrhythmias, recent myocardial infarction, uncompensated heart failure.",n_2606,,,,,,,
Phenotypes,Uncorrected hypokalaemia.,n_2607,,,,,,,
Phenotypes,Progressive supranuclear palsy.,n_2608,,,,,,,
Phenotypes,Dementia with Lewy bodies.,n_2609,,,,,,,
Phenotypes,Parkinson's disease.,n_2610,,,,,,,
Phenotypes,Blood dyscrasias.,n_2611,,,,,,,
Phenotypes,"Cardiovascular disease — an ECG may be required, particularly if physical examination identifies cardiovascular risk factors, personal history of cardiovascular disease.",n_2612,,,,,,,
Phenotypes,Conditions predisposing to seizures.,n_2613,,,,,,,
Phenotypes,Depression.,n_2614,,,,,,,
Phenotypes,Diabetes (may raise blood glucose).,n_2615,,,,,,,
Phenotypes,Epilepsy.,n_2616,,,,,,,
Phenotypes,History of jaundice.,n_2617,,,,,,,
Phenotypes,Myasthenia gravis.,n_2618,,,,,,,
Phenotypes,Parkinsonʼs disease (may be exacerbated).,n_2619,,,,,,,
Phenotypes,Photosensitization (may occur with higher dosages).,n_2620,,,,,,,
Phenotypes,Prostatic hypertrophy.,n_2621,,,,,,,
Phenotypes,Severe respiratory disease.,n_2622,,,,,,,
Phenotypes,Susceptibility to angle-closure glaucoma,n_2623,,,,,,,
Phenotypes,Bradycardia.,n_2624,,,,,,,
Phenotypes,Uncorrected electrolyte disturbances.,n_2625,,,,,,,
Phenotypes,Family history of QTc-interval prolongation.,n_2626,,,,,,,
Phenotypes,History of heavy alcohol exposure.,n_2627,,,,,,,
Phenotypes,Hyperthyroidism.,n_2628,,,,,,,
Phenotypes,Hypotension (including orthostatic hypotension).,n_2629,,,,,,,
Phenotypes,Prolactin-dependent tumours.,n_2630,,,,,,,
Phenotypes,Prolactinaemia.,n_2631,,,,,,,
Phenotypes,Risk factors for stroke.,n_2632,,,,,,,
Phenotypes,Hypersensitivity to risperidone or to any of the excipients.,n_2633,,,,,,,
Phenotypes,Acute porphyrias.,n_2634,,,,,,,
Phenotypes,Cataract surgery (risk of intra-operative floppy iris syndrome).,n_2635,,,,,,,
Phenotypes,Dehydration.,n_2636,,,,,,,
Stage,初期,n_2652,,,,,,,
Dosage,起始劑量5 mg/day 每日劑量  5-10 mg/day,n_2657,,,,,,,
Dosage,起始劑量: 3mg/day 每日劑量  6-12 mg/day,n_2660,,,,,,,
Treatment,Galantamine  Treatment (NICE),n_2661,,,,,,,
Dosage,起始劑量: 8mg/day 每日劑量   8-24 mg/day,n_2663,,,,,,,
Duration,每日兩次持續四週,n_2664,,,,,,,
Dosage,起始劑量: 5 mg/day 每日劑量   5-20mg/day,n_2667,,,,,,,
SideEffect,decreased appetite,n_2674,,,,,,,
SideEffect,Depressed,n_2682,,,,,,,
SideEffect,Weight lose,n_2697,,,,,,,
SideEffect,Hallucination,n_2702,,,,,,,
SideEffect,Myalgia,n_2703,,,,,,,
Phenotypes,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",n_2710,,,,,,,
Phenotypes,"Difficulties with basic activities of daily living (e.g. feeding,dressing).",n_2712,,,,,,,
Phenotypes,Fully dependent,n_2714,,,,,,,
Evidence,Moderate quality (Level B),n_2742,,,,,,,
Evidence,Moderate to Low quality,n_2746,,,,,,,
Dosage,5 mg/day for 12-24 week,n_2749,,,,,,,
Dosage,10 mg/day for 24-26 week,n_2750,,,,,,,
Population,Mild to Severe Alzheimer's Disease (MMSE 0-26) (ADAS-Cog),n_2751,,,,,,,
Dosage,6 - 12 mg/day twice daily 26 week,n_2754,,,,,,,
Dosage,9.5 mg/day patch 26 week,n_2758,,,,,,,
Dosage,24 mg/day 21-26 week,n_2762,,,,,,,
Population,Moderate to severe Alzheimer's Disease (MMSE < 20) (ADAS-Cog),n_2766,,,,,,,
SideEffect,Mortality,n_2779,,,,,,,
Effectiveness,Aerobic exercise is known to have cognition-enhancing effects,n_2784,,,,,,,
Effectiveness,"Improvements in performance, particularly in memory",n_2785,,,,,,,
Effectiveness,"Improve and maintain cognitive function, thus reducing the progression of cognitive deterioration.",n_2786,,,,,,,
Treatment,Galantamine Treatment (AmericanAcademy of Family Physicians),n_2790,,,,,,,
Treatment,Memantine Treatment (AmericanAcademy of Family Physicians),n_2799,,,,,,,
Evidence,High quality (Level B),n_2808,,,,,,,
Duration,4 to 6 weeks,n_2813,,,,,,,
Duration,3 weeks,n_2816,,,,,,,
Dosage,23 mg at bedtime,n_2818,,,,,,,
Effectiveness,improvement in global function and cognitive symptoms,n_2819,,,,,,,
Duration,2 weeks,n_2825,,,,,,,
Dosage,12 mg orally 2 times per day,n_2845,,,,,,,
Dosage,"1.5 mg orally 2 times per day for 2 weeks, then increase each dose in 1.5-mg increments every 2 weeks as tolerated to maximal dosage of 12 mg per day",n_2846,,,,,,,
Duration,4 weeks,n_2853,,,,,,,
Dosage,13.3-mg patch every 24 hours,n_2858,,,,,,,
Dosage,12mg 2 times per day,n_2870,,,,,,,
Dosage,24 mg per day,n_2882,,,,,,,
Dosage,10 mg 2 times per day,n_2897,,,,,,,
Dosage,28 mg orally per day,n_2912,,,,,,,
Dosage,Memantine:28 mg orally at bedtime,n_2941,,,,,,,
SideEffect,Atrioventricular block,n_2946,,,,,,,
SideEffect,Torsades de pointes,n_2956,,,,,,,
SideEffect,Infarction,n_2963,,,,,,,
SideEffect,Myocardial,n_2966,,,,,,,
SideEffect,Heart block,n_2979,,,,,,,
SideEffect,Hemorrhage,n_2980,,,,,,,
Phenotypes,Memory loss for recent events,n_2996,,,,,,,
Treatment,Memantine Treatment (Demenzen),n_3009,,,,,,,
Treatment,Donepezil Treatment (Demenzen),n_3017,,,,,,,
Duration,Review every 6 months,n_3020,,,,,,,
Effectiveness,small significant benefit on cognitive function and ADL,n_3021,,,,,,,
Population,Mild to moderate Alzheimer's Disease (MMSE 10-26),n_3022,,,,,,,
Treatment,Galantamine Treatment (Demenzen),n_3023,,,,,,,
Effectiveness,significant effect on ADL function at 24 weeks,n_3033,,,,,,,
Treatment,Rivastigmine Treatment (Demenzen),n_3035,,,,,,,
SideEffect,Gastrointestinal,n_3047,,,,,,,
SideEffect,Falls,n_3050,,,,,,,
Phenotypes,short-term memory loss,n_3060,,,,,,,
Phenotypes,Apathy,n_3061,,,,,,,
Phenotypes,Depression,n_3062,,,,,,,
Evidence,Low quality (Level C),n_3077,,,,,,,
Effectiveness,Enhancement of cognitive and social functioning,n_3105,,,,,,,
Effectiveness,"Typically involves guided practice on a set of standard tasks designed to reflect particular cognitive functions, such as memory, attention, language or executive function",n_3106,,,,,,,
Effectiveness,"Individualised approach to helping people with cognitive impairments in which those affected, and their families, work together with health care professionals to identify personally-relevant goals and devise strategies for addressing these. The emphasis is not on enhancing performance on cognitive tasks but on improving functioning in the everyday context.",n_3107,,,,,,,
Treatment,Combined Donepezil and Memantine Treatment (臺中榮總),n_3121,,,,,,,
Phenotypes,記憶障礙,n_3122,,,,,,,
Phenotypes,語言困難,n_3123,,,,,,,
Phenotypes,認知能力下降,n_3124,,,,,,,
Phenotypes,日常生活影響輕微,n_3125,,,,,,,
Phenotypes,行為改變,n_3126,,,,,,,
Phenotypes,記憶喪失,n_3127,,,,,,,
Phenotypes,語言與溝通障礙,n_3128,,,,,,,
Phenotypes,行為問題,n_3129,,,,,,,
Phenotypes,定向感障礙,n_3130,,,,,,,
Phenotypes,功能下降,n_3131,,,,,,,
Phenotypes,嚴重記憶喪失,n_3132,,,,,,,
Phenotypes,嚴重語言障礙,n_3133,,,,,,,
Phenotypes,嚴重行為失控,n_3134,,,,,,,
Phenotypes,生活完全依賴他人,n_3135,,,,,,,
Phenotypes,身體機能退化,n_3136,,,,,,,
Duration,4-6 week,n_3141,,,,,,,
Dosage,Donepezil 5-10 mg/day,n_3143,,,,,,,
Effectiveness,緩解BPSD,n_3144,,,,,,,
Dosage,Rivastigmine 1.5-4.5 mg/day,n_3152,,,,,,,
Dosage,Rivastigmine 4.5-6 mg/day,n_3155,,,,,,,
Dosage,Rivastigmine Patch 9.5 mg/day,n_3163,,,,,,,
Dosage,Galantamine 8 mg/day,n_3168,,,,,,,
Dosage,Galantamine 16-24 mg/day,n_3171,,,,,,,
Dosage,Memantine 5 mg/day,n_3176,,,,,,,
Duration,2 week,n_3177,,,,,,,
Effectiveness,減輕躁動症狀,n_3180,,,,,,,
Effectiveness,腎功能不佳者 (Creatinine Clearance 40 - 60 ml/ min/1.73 m2),n_3186,,,,,,,
SideEffect,Loss of appetite,n_3195,,,,,,,
SideEffect,Skin reaction,n_3218,,,,,,,
Effectiveness,Sensory Stimulation,n_3245,,,,,,,
Effectiveness,Maintains cognitive functions and slows the rate of decline.,n_3246,,,,,,,
Effectiveness,"Promotes social participation, improves mood, and fosters interaction and a sense of happiness.",n_3247,,,,,,,
Effectiveness,"Provides sensory stimulation, enhances focus and expression, boosts self-esteem, and improves group interaction.",n_3248,,,,,,,
Effectiveness,"Improves physical fitness, balance, and muscle strength, slows cognitive decline, and enhances quality of life.",n_3249,,,,,,,
Effectiveness,"Reinforces awareness of time, place, and people, boosts self-esteem, and reduces problematic behaviors.",n_3250,,,,,,,
Effectiveness,"Improves mood, stimulates brain activity, and enhances life satisfaction",n_3251,,,,,,,
Phenotypes,Severe bradycardia,n_3257,,,,,,,
Phenotypes,Heart conduction block,n_3258,,,,,,,
Phenotypes,病患對藥物順從性不佳,n_3259,,,,,,,
Phenotypes,病患在使用藥物後智能、精神行為、或生活功能減退速度反較治療前快,n_3260,,,,,,,
Phenotypes,病患對藥物產生無法忍受之副作用,n_3261,,,,,,,
Phenotypes,疾病末期治療已無意義,n_3262,,,,,,,
Phenotypes,Impaired renal function (Creatinine clearance < 40 mL/min/1.73m² requires dosage adjustment),n_3281,,,,,,,
Treatment,Donepezil Treatment (Alzheimer Society of B.C.),n_3286,,,,,,,
Treatment,Rivastigmine Treatment (Alzheimer Society of B.C.),n_3287,,,,,,,
Treatment,Galantamine Treatment (Alzheimer Society of B.C.),n_3288,,,,,,,
Treatment,Memantine Treatment(Alzheimer Society of B.C.),n_3292,,,,,,,
Treatment,Memantine Treatment (Alzheimer Society of B.C.),n_3294,,,,,,,
Phenotypes,Memory lapses,n_3295,,,,,,,
Phenotypes,Forgetting familiar names and locations of objects,n_3296,,,,,,,
Phenotypes,These lapses typically are not obvious to others,n_3297,,,,,,,
Phenotypes,Mild Forgetfulness,n_3298,,,,,,,
Phenotypes,Difficulty learning new things,n_3299,,,,,,,
Phenotypes,Difficulty concentrating or limited attention span,n_3300,,,,,,,
Phenotypes,"Problems with orientation (e.g., getting lost)",n_3301,,,,,,,
Phenotypes,"Communication difficulties (e.g., finding the right word)",n_3302,,,,,,,
Phenotypes,Loss or misplacement of valuable objects,n_3303,,,,,,,
Phenotypes,Difficulty handling problems at work,n_3304,,,,,,,
Phenotypes,"Noticeable issues to family, friends, or co-workers",n_3305,,,,,,,
Phenotypes,Some memory loss involving one's personal history,n_3306,,,,,,,
Phenotypes,"Difficulty with complex tasks, e.g. managing finances, shopping, travel",n_3307,,,,,,,
Phenotypes,Decreased knowledge of current events and recent events,n_3308,,,,,,,
Phenotypes,"Impaired ability to perform challenging mental arithmetic, e.g. counting backward from 75 by 7",n_3309,,,,,,,
Phenotypes,"Major gaps in memory, e.g. phone numbers or names of close family members ",n_3310,,,,,,,
Phenotypes,Help is needed with day-to-day tasks,n_3311,,,,,,,
Phenotypes,"Continued memory loss, e.g. occasionally forgetting the name of a spouse or primary caregiver",n_3312,,,,,,,
Phenotypes,"Loss of awareness of recent events and experiences in their lives, e.g. not remembering what they had for lunch or their child’s graduation",n_3313,,,,,,,
Phenotypes,"Assistance is needed with activities of daily living, e.g. getting dressed, bathing",n_3314,,,,,,,
Phenotypes,Difficulties counting,n_3315,,,,,,,
Phenotypes,"Personality and emotion changes such as confusion, anxiety, suspiciousness, anger, sadness/depression, hostility, apprehension, delusion and agitation",n_3316,,,,,,,
Phenotypes,Obsessions such as repetition of simple activities- Disruption of normal sleep/waking cycle,n_3317,,,,,,,
Phenotypes,Increasing episodes of incontinen,n_3318,,,,,,,
Phenotypes,Severe cognitive impairment,n_3319,,,,,,,
Phenotypes,Vocabulary becomes limited and verbal abilities eventually disappear,n_3320,,,,,,,
Phenotypes,Loss of ability to walk independently and sit without support,n_3321,,,,,,,
Phenotypes,Help is needed with eating and using the toilet; usually incontinent,n_3322,,,,,,,
Dosage,Donepezil 10 mg/day,n_3344,,,,,,,
Dosage,Galantamine 24 mg/day,n_3348,,,,,,,
Dosage,Rivastigmine 6-12 mg/day,n_3352,,,,,,,
Dosage,Memantine 20 mg/day,n_3360,,,,,,,
Dosage,Memantine 28 mg/day,n_3364,,,,,,,
Effectiveness,attenuates worsening of physical function and activities of daily living,n_3371,,,,,,,
Effectiveness,"improving BPSD, including anxiety",n_3372,,,,,,,
Treatment,Suvorexant,n_3375,,,,,,,
Phenotypes,memory loss ,n_3390,,,,,,,
Phenotypes,cognitive ability loss,n_3391,,,,,,,
Phenotypes,Difficultly coming up with the right word or name.,n_3392,,,,,,,
Phenotypes,Difficultly remembering names when introduced to new people.,n_3393,,,,,,,
Phenotypes,Having difficulty performing tasks in social or work settings.,n_3394,,,,,,,
Phenotypes,Forgetting material that was just read.,n_3395,,,,,,,
Phenotypes,Losing or misplacing a valuable object.,n_3396,,,,,,,
Phenotypes,Experiencing increased trouble with planning or organizing.,n_3397,,,,,,,
Phenotypes,Being forgetful of events or personal history.,n_3398,,,,,,,
Phenotypes,"Feeling moody or withdrawn, especially in socially or mentally challenging situations.",n_3399,,,,,,,
Phenotypes,"Being unable to recall information about themselves like their address or telephone number, and the high school or college they attended.",n_3400,,,,,,,
Phenotypes,Experiencing confusion about where they are or what day it is.,n_3401,,,,,,,
Phenotypes,Requiring help choosing proper clothing for the season or the occasion.,n_3402,,,,,,,
Phenotypes,Having trouble controlling their bladder and bowels.,n_3403,,,,,,,
Phenotypes,"Experiencing changes in sleep patterns, such as sleeping during the day and becoming restless at night.",n_3404,,,,,,,
Phenotypes,Showing an increased tendency to wander and become lost.,n_3405,,,,,,,
Phenotypes,"Demonstrating personality and behavioral changes, including suspiciousness and delusions or compulsive, repetitive behavior like hand-wringing or tissue shredding.",n_3406,,,,,,,
Phenotypes,Require around-the-clock assistance with daily personal care.,n_3407,,,,,,,
Phenotypes,Lose awareness of recent experiences as well as of their surroundings.,n_3408,,,,,,,
Phenotypes,"Experience changes in physical abilities, including walking, sitting and, eventually, swallowing",n_3409,,,,,,,
Phenotypes,Have difficulty communicating.,n_3410,,,,,,,
Phenotypes,"Become vulnerable to infections, especially pneumonia.",n_3411,,,,,,,
Population,MCI to Mild Alzheimer's Disease,n_3414,,,,,,,
Population,Mild to severe Alzheimer's Disease,n_3420,,,,,,,
Population,Mild to moderate Alzheimer's Disease,n_3423,,,,,,,
Population,Moderate to severe Alzheimer's Disease,n_3429,,,,,,,
Population,Agitation associated with dementia due to Alzheimer's disease,n_3436,,,,,,,
Population,Insomnia,n_3439,,,,,,,
SideEffect,ARIA,n_3441,,,,,,,
SideEffect,headache,n_3442,,,,,,,
SideEffect,Infusion-related reactions,n_3443,,,,,,,
SideEffect,Increased frequency of bowel movements,n_3450,,,,,,,
SideEffect,Sleepiness,n_3464,,,,,,,
SideEffect,Common cold symptoms,n_3466,,,,,,,
SideEffect,Restlessness or feeling like  need to move,n_3467,,,,,,,
SideEffect,Impaired alertness and motor coordination,n_3468,,,,,,,
SideEffect,Worsening of depression or suicidal thinking,n_3469,,,,,,,
SideEffect,Complex sleep behaviors,n_3470,,,,,,,
SideEffect,Sleep paralysis,n_3471,,,,,,,
SideEffect,Compromised respiratory function,n_3472,,,,,,,
Therapy,Maintain regular times for meals and for going to bed and getting up,n_3473,,,,,,,
Therapy,Seek morning sunlight exposure,n_3474,,,,,,,
Therapy,"Encourage regular daily exercise, but no later than four hours before bedtime",n_3475,,,,,,,
Therapy,"Avoid alcohol, caffeine and nicotine",n_3476,,,,,,,
Therapy,Treat any pain,n_3477,,,,,,,
Therapy,"If the person is taking a cholinesterase inhibitor (tacrine, donepezil, rivastigmine or galantamine), avoid giving the medicine before bed",n_3478,,,,,,,
Therapy,Make sure the bedroom temperature is comfortable,n_3479,,,,,,,
Therapy,Provide nightlights and security objects,n_3480,,,,,,,
Therapy,"If the person awakens, discourage staying in bed while awake; use the bed only for sleep",n_3481,,,,,,,
Therapy,Discourage watching television during periods of wakefulness,n_3482,,,,,,,
Population,Mild to Severe Alzheimer's Disease (MMSE 1-26),n_3543,,,,,,,
Population,Mild to severe Alzheimer's Disease (MMSE 1-26),n_3597,,,,,,,
Treatment,Rivastigmine Treatment(Indian Psychiatric Society),n_3610,,,,,,,
Duration,6 months,n_3636,,,,,,,
Prevent,Statins_BernadetteMcGuinness,n_3638,,,,,,,
Treatment,melatonin_JennyMcCleery,n_3640,,,,,,,
Treatment,melatonin receptor agonist_JennyMcCleery,n_3641,,,,,,,
Treatment,trazodone_JennyMcCleery,n_3642,,,,,,,
Treatment,orexin antagonists_JennyMcCleery,n_3643,,,,,,,
Prevent, non‐selective NSAID naproxen_FionnualaJordan,n_3660,,,,,,,
Duration,4.7years,n_3664,,,,,,,
Duration,734 days,n_3666,,,,,,,
Duration,17.6 months,n_3670,,,,,,,
Duration,115 weeks,n_3672,,,,,,,
Treatment,Cerebrolysin_Shuhui Cui,n_3673,,,,,,,
Dosage,5 or 10mg/day,n_3683,,,,,,,
Dosage,3~12mg/day,n_3685,,,,,,,
Prevent,vitamin B6_JennyMcCleery,n_3686,,,,,,,
Prevent,vitamin B12_JennyMcCleery,n_3687,,,,,,,
Prevent,vitamin E_JennyMcCleery,n_3688,,,,,,,
Duration,16 weeks,n_3696,,,,,,,
Duration,26 or 52 weeks,n_3702,,,,,,,
Duration,12~52 weeks,n_3708,,,,,,,
Duration,24~26 weeks,n_3715,,,,,,,
Duration,3~14 weeks,n_3721,,,,,,,
Therapy,Dance movement_Vicky Karkou,n_3722,,,,,,,
Duration,6~48 months,n_3737,,,,,,,
Treatment,Antipsychotic_Viktoria Mühlbauer,n_3738,,,,,,,
Duration,1~5 years,n_3742,,,,,,,
drug,Bethanechol,n_3743,,,,,,,
drug,Ketoconazole,n_3744,,,,,,,
drug,Oxybutynin,n_3745,,,,,,,
drug,Tolterodine,n_3746,,,,,,,
drug,Metoclopramide,n_3747,,,,,,,
drug,Fluvoxamine,n_3753,,,,,,,
drug,Fluroxetine,n_3754,,,,,,,
drug,Paroxetine,n_3755,,,,,,,
drug,Ranitidine,n_3756,,,,,,,
drug,Cimetidine,n_3757,,,,,,,
drug,Hydrochlorothiazide,n_3758,,,,,,,
drug,Sodium bicarbonate,n_3759,,,,,,,
drug,Antimuscarinic drugs,n_3760,,,,,,,
drug,Antipsychotics,n_3763,,,,,,,
drug,Beta-blockers,n_3766,,,,,,,
drug,Liver enzyme inhibitors,n_3769,,,,,,,
drug,Liver enzyme inducers,n_3770,,,,,,,
drug,Antimuscarinics ,n_3773,,,,,,,
drug,Dopaminergics,n_3774,,,,,,,
drug,N-methyl-D-aspartate (NMDA)-antagonists ,n_3775,,,,,,,
drug,Warfarin,n_3776,,,,,,,
drug,Barbiturates,n_3778,,,,,,,
drug,Baclofen and dantrolene,n_3779,,,,,,,
source,American Academy of Family Physicians,es_1,Guideline,American Academy of Family Physicians,Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1,,USA
source,Alzheimer Society,es_2,Guideline,Alzheimer Society,Dementia treatment options and developments,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1,,Canada
source,Alzheimer's Association,es_3,Guideline,Alzheimer's Association,"Medications for Memory, Cognition and Dementia-Related Behaviors",https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1,,USA
source,The Association of Scientific Medical Societies in Germany,es_4,Guideline,The Association of Scientific Medical Societies in Germany,S3-Leitlinie Demenzen Langfassung,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1,,Germany
source,Cognitive Decline Partnership Centre,es_5,Guideline,Cognitive Decline Partnership Centre,Clinical Practice Guidelines and Principles of Care for People with Dementia,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1,,Australia
source,Cochrane Library,es_6,Systematic Review,Cochrane Library,Cholinesterase inhibitors for Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005593/abstract,2006/1/25,,
source,Cochrane Library,es_7,Systematic Review,Cochrane Library,Memantine for dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub5/full,2006/4/19,,
source,Cochrane Library,es_8,Systematic Review,Cochrane Library,Exercise programs for people with dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006489.pub4/full,2015/4/15,,
source,Cochrane Library,es_9,Systematic Review,Cochrane Library,Music therapy for people with dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003477.pub2/full,2003/10/20,,
source,Cochrane Library,es_10,Systematic Review,Cochrane Library,Donepezil for dementia due to Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021/1/1,,
source,Cochrane Library,es_11,Systematic Review,Cochrane Library,Galantamine for Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full,2015/1/1,,
source,Cochrane Library,es_12,Systematic Review,Cochrane Library,Rivastigmine for Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub2/full,2004/1/1,,
source,Cochrane Library,es_13,Systematic Review,Cochrane Library,Memantine for dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub5/full,2019/3/20,30891742.0,
source,Electronic Medicines Compendium,es_14,Database,Electronic Medicines Compendium,electronic medicines compendium,https://www.medicines.org.uk/emc,2023/1/15,,
source,International Journal of Neuropsychopharmacology,es_15,Journal Article,International Journal of Neuropsychopharmacology,Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimers Disease: A Systematic Review and Meta-Analysis ,https://academic.oup.com/ijnp/article/18/5/pyu115/786398?login=false,2017/7/1,,
source,Journal of the American Medical Association,es_16,Journal Article,Journal of the American Medical Association,Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease,https://jamanetwork.com/journals/jama/fullarticle/1810379#google_vignette,2014/1/1,,
source,Japanese Society of Neurology,es_17,Guideline,Japanese Society of Neurology,Clinical Practice Guideline for Dementia 2017,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1,,Japan
source,Ministry of Health Malaysia,es_18,Guideline,Ministry of Health Malaysia,MANAGEMENT OF DEMENTIA (THIRD EDITION),https://www.moh.gov.my/moh/resources/Main%20Banner/2021/Jun/Draft_CPG_Management_of_Dementia_(Third_Edition).pdf,2021/1/31,,Malaysia
source,成大指引,es_19,Guideline,成大指引,成大指引,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1,,Taiwan
source,National Institute for Health and Care Excellence,es_20,Guideline,National Institute for Health and Care Excellence,The NICE Clinical Knowledge Summaries,https://cks.nice.org.uk/topics/dementia/,2024/4/1,,UK
source,Health Technol Assess,es_21,Journal Article,Health Technol Assess,"The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model",https://pubmed.ncbi.nlm.nih.gov/22541366/,2012/1/1,22541366.0,
source,臺中榮總,es_22,Guideline,臺中榮總,臺中榮總,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21,,Taiwan
source,Nederlands Huisartsen Genootschap,es_23,Guideline,Nederlands Huisartsen Genootschap,NHG-Standaard,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1,,Netherlands
source,kaypahoito,es_24,Guideline,kaypahoito,kaypahoito,https://www.kaypahoito.fi/nix00521,2023/11/12,,Finland
source,Indian Psychiatric Society,es_25,Guideline,Indian Psychiatric Society,Indian Psychiatric Society,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1,,Indian
source,Cochrane Library,es_31,Systematic Review,Cochrane Library,"Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia",https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009081.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/3,,
source,Cochrane Library,es_32,Systematic Review,Cochrane Library,Statins for the prevention of dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003160.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2016/1/4,,
source,Cochrane Library,es_33,Systematic Review,Cochrane Library,Pharmacotherapies for sleep disturbances in dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009178.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/11/15,,
source,Cochrane Library,es_34,Systematic Review,Cochrane Library,Memantine for dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/3/20,,
source,Cochrane Library,es_35,Systematic Review,Cochrane Library,Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30,,
source,Cochrane Library,es_36,Systematic Review,Cochrane Library,Cerebrolysin for vascular dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008900.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/11/11,,
source,Cochrane Library,es_37,Systematic Review,Cochrane Library,Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013306.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/22,,
source,Cochrane Library,es_38,Systematic Review,Cochrane Library,Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011905.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/11/1,,
source,Cochrane Library,es_39,Systematic Review,Cochrane Library,Souvenaid for Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011679.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/12/15,,
source,Cochrane Library,es_40,Systematic Review,Cochrane Library,Latrepirdine for Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009524.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/4/21,,
source,Cochrane Library,es_41,Systematic Review,Cochrane Library,Rivastigmine for Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/9/22,,
source,Cochrane Library,es_42,Systematic Review,Cochrane Library,Donepezil for dementia due to Alzheimer's disease,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/6/18,,
source,Cochrane Library,es_43,Systematic Review,Cochrane Library,Cannabinoids for the treatment of dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012820.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/9/17,,
source,Cochrane Library,es_44,Systematic Review,Cochrane Library,Dance movement therapy for dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011022.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2023/8/7,,
source,Cochrane Library,es_45,Systematic Review,Cochrane Library,Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2024/11/5,,
source,Cochrane Library,es_46,Systematic Review,Cochrane Library,Omega‐3 fatty acids for the treatment of dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009002.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2016/4/11,,
source,Cochrane Library,es_47,Systematic Review,Cochrane Library,Vitamin E for Alzheimer's dementia and mild cognitive impairment,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002854.pub5/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2017/4/18,,
source,Cochrane Library,es_48,Systematic Review,Cochrane Library,Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013304.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/12/17,,
source,Cochrane Library,es_49,Systematic Review,Cochrane Library,Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004034.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/5/24,,
source,IQWiG,es_50,Systematic Review,IQWiG,Cholinesterasehemmer bei Alzheimer Demenz,https://www.iqwig.de/download/a05-19a_abschlussbericht_cholinesterasehemmer_bei_alzheimer_demenz.pdf,2007/2/7,,
source,DrugBank,es_51,Database,DrugBank,DrugBank,https://go.drugbank.com/releases/latest,2025/1/2,,
source,Clinical Trials,es_52,Clinical trial,Clinical Trials,Senolytic Therapy to Modulate Progression of Alzheimer's Disease,https://clinicaltrials.gov/study/NCT04063124,2023/3/6,,
source,Clinical Trials,es_53,Clinical trial,Clinical Trials,Bryostatin Treatment of Moderately Severe Alzheimer's Disease,https://clinicaltrials.gov/study/NCT04538066,2024/7/31,,
source,Clinical Trials,es_54,Clinical trial,Clinical Trials,A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD,https://clinicaltrials.gov/study/NCT05686044,2025/4/29,,
source,Clinical Trials,es_55,Clinical trial,Clinical Trials,A Study of Seltorexant in Participants With Probable Alzheimer's Disease,https://clinicaltrials.gov/study/NCT05307692,2024/11/25,,
source,Clinical Trials,es_56,Clinical trial,Clinical Trials,"Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients",https://clinicaltrials.gov/study/NCT04388254,2025/4/22,,
source,Clinical Trials,es_57,Clinical trial,Clinical Trials,ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease,https://clinicaltrials.gov/study/NCT04488419,2025/4/4,,
source,Clinical Trials,es_58,Clinical trial,Clinical Trials,A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease,https://clinicaltrials.gov/study/NCT05104463,2025/1/23,,
source,Clinical Trials,es_59,Clinical trial,Clinical Trials,Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease,https://clinicaltrials.gov/study/NCT05422885,2025/3/17,,
source,Clinical Trials,es_60,Clinical trial,Clinical Trials,A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2),https://clinicaltrials.gov/study/NCT04437511,2023/4/14,,
source,MONDO,s_0,PrimeKG,MONDO,,,,,
source,MONDO_grouped,s_1,PrimeKG,MONDO_grouped,,,,,
source,REACTOME,s_2,PrimeKG,REACTOME,,,,,
source,HPO,s_3,PrimeKG,HPO,,,,,
source,NCBI,s_4,PrimeKG,NCBI,,,,,
source,CTD,s_5,PrimeKG,CTD,,,,,
source,pubmed,s_6,PrimeKG,pubmed,,,,,
source,IJN,s_7,PrimeKG,IJN,,,,,
